Shionogi & Co., Ltd. (4507.T) JPX

2,798.00

-25(-0.89%)

Updated at June 03 09:25AM

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Isao Teshirogi	Chief Executive Officer, President & Representative Director	269M	1959
Masashi Deguchi	Corporate Officer & Senior Vice President of Sustainability Management Division	0	N/A
Kazuhiro Hatanaka	Senior Executive Officer & Senior Vice President of Corporate Supervisory Unit	0	N/A
Takeshi Shiota	Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics & Compliance Management Div.	0	N/A
Toshinobu Iwasaki	Senior Executive Officer & Senior Vice President of Healthcare Business Supervisory Unit	0	N/A
Yoshimasa Kyokawa	Vice President of Corporate Communications & Secretary Office	0	N/A
Yoshihiro Furuya	Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office	0	N/A
Akira Kato	Senior Executive Officer and Senior Vice President of Supply Supervisory Unit	0	N/A
John Apeler Keller	Senior Executive Officer, SVice President of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director	0	1964
Takuji Fujiwara	Accounting & Finance Manager	0	N/A

Name

Title

Pay

Year Born

Isao Teshirogi

Chief Executive Officer, President & Representative Director

269M

1959

Masashi Deguchi

Corporate Officer & Senior Vice President of Sustainability Management Division

N/A

Kazuhiro Hatanaka

Senior Executive Officer & Senior Vice President of Corporate Supervisory Unit

N/A

Takeshi Shiota

Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics & Compliance Management Div.

N/A

Toshinobu Iwasaki

Senior Executive Officer & Senior Vice President of Healthcare Business Supervisory Unit

N/A

Yoshimasa Kyokawa

Vice President of Corporate Communications & Secretary Office

N/A

Yoshihiro Furuya

Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office

N/A

Akira Kato

Senior Executive Officer and Senior Vice President of Supply Supervisory Unit

N/A

John Apeler Keller

Senior Executive Officer, SVice President of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director

1964

Takuji Fujiwara

Accounting & Finance Manager

N/A

Description

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.